ResearcherUniversity of IowaActive in the last 2 years
Kellie L. Bodeker
Matched on ORCID iD 0000-0002-8930-2819; OpenAlex author ID A5055097161. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 20
2012: 1 paper · 2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper
Papers 5
- A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer. Co-author DOI 10.1016/j.redox.2024.103375↗
- Pharmacologic Ascorbate Reduces Radiation-Induced Normal Tissue Toxicity and Enhances Tumor Radiosensitization in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-18-1680↗
- Consuming a Ketogenic Diet while Receiving Radiation and Chemotherapy for Locally Advanced Lung Cancer and Pancreatic Cancer: The University of Iowa Experience… Co-author DOI 10.1667/rr14668.1↗
- Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Co-author DOI 10.1007/s00280-013-2070-8↗
- Comparison of response evaluation criteria in solid tumors with volumetric measurements for estimation of tumor burden in pancreatic adenocarcinoma and hepatoc… First author DOI 10.1016/j.amjsurg.2012.07.007↗
Closest collaborators
The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- John Michael Buatti · 4 shared papers, 2012–2024 · strength 0.32
- Paper A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer. DOI 10.1016/j.redox.2024.103375↗
- Paper Pharmacologic Ascorbate Reduces Radiation-Induced Normal Tissue Toxicity and Enhances Tumor Radiosensitization in Pancr… DOI 10.1158/0008-5472.can-18-1680↗
- Paper Consuming a Ketogenic Diet while Receiving Radiation and Chemotherapy for Locally Advanced Lung Cancer and Pancreatic C… DOI 10.1667/rr14668.1↗
- Daniel Berg · 4 shared papers, 2013–2024 · strength 0.31
- Paper A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer. DOI 10.1016/j.redox.2024.103375↗
- Paper Pharmacologic Ascorbate Reduces Radiation-Induced Normal Tissue Toxicity and Enhances Tumor Radiosensitization in Pancr… DOI 10.1158/0008-5472.can-18-1680↗
- Paper Consuming a Ketogenic Diet while Receiving Radiation and Chemotherapy for Locally Advanced Lung Cancer and Pancreatic C… DOI 10.1667/rr14668.1↗
- Joseph J. Cullen · 4 shared papers, 2012–2024 · strength 0.30
- Paper A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer. DOI 10.1016/j.redox.2024.103375↗
- Paper Pharmacologic Ascorbate Reduces Radiation-Induced Normal Tissue Toxicity and Enhances Tumor Radiosensitization in Pancr… DOI 10.1158/0008-5472.can-18-1680↗
- Paper Comparison of response evaluation criteria in solid tumors with volumetric measurements for estimation of tumor burden … DOI 10.1016/j.amjsurg.2012.07.007↗
- Bryan G. Allen · 3 shared papers, 2017–2024 · strength 0.28
- Paper A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer. DOI 10.1016/j.redox.2024.103375↗
- Paper Pharmacologic Ascorbate Reduces Radiation-Induced Normal Tissue Toxicity and Enhances Tumor Radiosensitization in Pancr… DOI 10.1158/0008-5472.can-18-1680↗
- Paper Consuming a Ketogenic Diet while Receiving Radiation and Chemotherapy for Locally Advanced Lung Cancer and Pancreatic C… DOI 10.1667/rr14668.1↗
- Garry R. Buettner · 3 shared papers, 2013–2024 · strength 0.26
- Paper A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer. DOI 10.1016/j.redox.2024.103375↗
- Paper Pharmacologic Ascorbate Reduces Radiation-Induced Normal Tissue Toxicity and Enhances Tumor Radiosensitization in Pancr… DOI 10.1158/0008-5472.can-18-1680↗
- Paper Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): … DOI 10.1007/s00280-013-2070-8↗
- Naomi H. Fei · 1 shared paper, 2024 · strength 0.16
- Chandrikha Chandrasekharan · 1 shared paper, 2024 · strength 0.16
- Mandana Kamgar · 1 shared paper, 2024 · strength 0.16
- Joseph Michael Caster · 1 shared paper, 2024 · strength 0.16
- Douglas Robert Spitz · 2 shared papers, 2017–2018 · strength 0.12
- Paper Pharmacologic Ascorbate Reduces Radiation-Induced Normal Tissue Toxicity and Enhances Tumor Radiosensitization in Pancr… DOI 10.1158/0008-5472.can-18-1680↗
- Paper Consuming a Ketogenic Diet while Receiving Radiation and Chemotherapy for Locally Advanced Lung Cancer and Pancreatic C… DOI 10.1667/rr14668.1↗
- Juan Du · 2 shared papers, 2013–2018 · strength 0.10
- Paper Pharmacologic Ascorbate Reduces Radiation-Induced Normal Tissue Toxicity and Enhances Tumor Radiosensitization in Pancr… DOI 10.1158/0008-5472.can-18-1680↗
- Paper Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): … DOI 10.1007/s00280-013-2070-8↗
- Jessemae L. Welsh · 2 shared papers, 2012–2013 · strength 0.07
- Paper Comparison of response evaluation criteria in solid tumors with volumetric measurements for estimation of tumor burden … DOI 10.1016/j.amjsurg.2012.07.007↗
- Paper Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): … DOI 10.1007/s00280-013-2070-8↗
- Matthew S. Alexander · 1 shared paper, 2018 · strength 0.07
- Brianne R. O’Leary · 1 shared paper, 2018 · strength 0.07
- Justin G. Wilkes · 1 shared paper, 2018 · strength 0.07
- Amir Zahra · 1 shared paper, 2017 · strength 0.05
- Mark Levine · 1 shared paper, 2013 · strength 0.03
- Thorvardur Ragnar Halfdanarson · 1 shared paper, 2013 · strength 0.03
- Jeanne Drisko · 1 shared paper, 2013 · strength 0.03
- Nelson S. Yee · 1 shared paper, 2013 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.